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Wegener’s Granulomatosis (WG) is an idiopathic granulomatosis autoimmune vasculitis that
primarily affects small vessels and is associated with glomerulonephritis and pulmonary granu-
lomatous vasculitis. Anti-neutrophil cytoplasmic auto-antibodies (cANCA) against proteinase-3
are used to identify WG, but ANCA titers are not present in some patients with the localized
disease. The objective of this study was to develop an antibody array to help identify protein
expression patterns in serum from patients with WG as compared to normals. The arrays were
tested for limits of detection, background, and cross reactivity using standard proteins. The
arrays were hybridized with either normal patient serum (n = 30) or with serum samples from a
population of WG patients (n = 26) that were age and sex matched. Data analysis and curve fit-
ting of the standard dilution series calculated r2 values and determined a sensitivity of ,50 pg/
mL for the majority of proteins. A total of 24 proteins were assessed. Several statistically signifi-
cant increases (p,0.05) were seen in the expression of: angiotensin converting enzyme-I, IFN-g,
IL-8, s-ICAM-1 and s-VCAM in WG patients as compared to controls. Utilizing the antibody
microarray technology has led to the identification of potential biomarkers of vascular injury in
the serum of WG patients.
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1 Introduction
Vasculitis is a heterogeneous group of diseases linked by
inflammation in the blood vessels. Although the exact
etiology is unknown, in many cases vasculitic diseases are
immune mediated, with immune complexes and delayed-
type hypersensitivity reactions present in the affected ves-
sels [1–6]. The categorization of vasculitic diseases has his-
torically been based on size, type and location of the ves-
sels involved. Although not all clinical presentations fit
into one category it provides standard criteria for vasculitis
identification [7–10]. Wegener’s granulomatosis (WG),
originally identified in 1936, is a form of systemic vasculi-
tis characterized by a triad of arthritis, pulmonary granu-
lomatosis vasculitis and glomerulonephritis [11]. Currently,
WG is described as an inflammation of small to medium
size vessels often leading to necrotic lesions and clinically
manifesting an “ELK” triad (upper respiratory, lung and
kidney) in the systemic disease [2, 4, 12, 13]. The diagnos-
tic confirmation of vasculitis usually requires a biopsy
along with clinical evaluation and evidence of anti-neu-
trophil cytoplasmic auto-antibodies (ANCA); pANCA (peri-
nuclear) and cANCA (cytoplasmic) [14–18]. WG is com-
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monly associated with proteinase-3 ANCA (cANCA) auto-
antibodies in the majority of patients. However, in the
localized disease state around 50% of the patients lack
cANCA titer [19]. While cANCA titer provides a strong
positive correlation to WG the elevation is not always
present. Alternatively, elevations in pANCA titer are asso-
ciated with WG but are also seen in a range of other auto-
immune diseases [19, 20]. Therefore, there is a need to
define additional biomarkers for the accurate early detec-
tion of WG or other types of vasculitis.
Immune system markers such as cytokines, cell surface
antigens and adhesion molecules have been assessed in
patients with vasculitis. However, the majority of this work
was done on individual analytes or from ex vivo experiments
[19, 21–37]. The majority of the published studies have
focused on a range of vasculitic diseases with few con-
centrating on WG.
Antibody arrays are a solid phase proteomic screening
technology that can be designed for custom applications [38–
40]. There are different types of antibody microarrays such as
dual label ratios [41], hapten labeled protein lysates (Biotin
and DNP) [42] or micro-ELISA [38] based arrays. The anti-
body arrays to screen WG patient’s serum were designed
using a micro-ELISA based method (i.e. analyte specific cap-
ture and detection antibodies). Antibody pairs that are opti-
mized for classical ELISA technology were used for the
development of our antibody arrays. Once the array was
designed and tested with standard proteins, it was hybridized
with normal and WG patient’s serum.
The goal of this study was to design and implement a
high-throughput, semi-quantitative antibody array to evalu-
ate the protein expression patterns in serum samples from
WG patients as compared to normal controls.
2 Materials and methods
2.1 Samples
Normal human serum (n = 30) was obtained from the Pfi-
zer CRC clinic (Protocol #394-0) and serum from patients
diagnosed with WG (n = 26) in varying disease stages, was
obtained from the University of Michigan (Protocol #IRB
2000-0005). Normal human serum was defined as taking
no over the counter pain medicines for one week, no ste-
roidal anti-inflammatory drugs for at least six months, and
no overt signs of illness. WG serum samples were taken
from patients with high cANCA titers (1:160) and histo-
logical evidence of active disease. However, the patient
population was heterogeneous (i.e. different stages and
treatment of the disease) and sometimes associated with
other auto-immune diseases. The serum samples were age
and sex matched. Vasculitis affected patients had a mean
age of 53 6 22 with 45% females, whereas the normal
patient population had a mean age of 51 6 23 with 48%
females.
2.2 Antibody array development and manufacture
Antibody microarrays were generated using commercially
available antibody pairs and standard proteins (R&D Sys-
tems, Minneapolis, MN). Antibody arrays were spotted using
a Piezorray™ (PerkinElmer, Boston, MA) following standard
protocols targeting to 16 specific sub-arrays designed to work
with the ProPlate™ system (Grace Bio-labs/Molecular Probes,
Eugene, OR). Capture antibodies were diluted in spotting
buffer (100 mM NaHPO4 (pH 9.0), 50 mM NaCl, 50 mM
Trehalose and 5% glycerol (Sigma, St. Louis, MO) and spot-
ted onto EpoxyES microarray slides (Erie Scientific, Ports-
mouth, NH) [39]. As a control for non-specific binding, iso-
type control and non-specific IgG antibodies were spotted on
the array. In initial studies the capture antibody was diluted
at a range of concentrations (25 mg/mL to 500 mg/mL) that
were tested with mixed standards in phosphate buffered sa-
line, 5% BSAwith 0.01% Tween-20 (Gibco/Invitrogen, Carls-
bad, CA) (range: 1.22 to 5000 pg/mL) with the detection
antibody diluted 1:200. Antibody microarrays were hybri-
dized, scanned and quantified as outlined below. Optimal
concentration of the secondary antibody was determined by
diluting and applying dilution antibodies (range: 1:200 to
1:1000) on slides with the capture antibody spotted that were
spotted at a range of concentrations with a dilution series of
the standards (range 24 to 1000 mg/mL). The standards with
an r2 of .0.95 were utilized for quantization. Antibody
microarrays were hybridized, scanned and quantified as
outlined below. An optimized antibody pair was defined as
providing a median fluorescent intensity (MFI) that respon-
ded in a dose dependent-manner and did not saturate the
MFI signal until the higher concentrations. Once an optimal
dilution was determined for both capture and detection
antibodies, standards were spiked into normal human
serum at 1000 pg/mL to determine percent recovery (goal:
85–115%). Standards were spiked individually into standard
diluent at 1000 pg/mL to determine cross reactivity and any
antibody that showed non-specific cross-reactivity was exclu-
ded. The standards were mixed together for the analysis of
the patient samples as reported previously [38]. Antibody
microarrays were hybridized, scanned and quantified as
outlined below. The antibody pairs were optimized for overall
performance instead of skewing to a lower limit that would
cause an early signal saturation and decrease overall linear
range. The lowest limit of detection was defined as the first
standard significantly different than the 0 point. Antibody
pairs that had a high lower limit of detection and did not
generate a good standard curve or low signal but did not
cross-react were considered non-quantifiable and were used
solely to determine relative expression based on MFI.
Normal and WG (vasculitis) diagnosed, human serum
was profiled on the antibody microarray. Antibody micro-
arrays were printed for the ProPlate™ system with the cap-
ture antibody spotted in triplicate. Standards were prepared
and the unknowns were diluted appropriately. Samples were
repeated in completely independent, randomized experi-
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ments to determine reproducibility. Antibody microarrays
were hybridized, scanned and quantified as outlined in Sec-
tion 2.3..
2.3 Antibody microarray hybridization
Standards were diluted into Tris-buffered saline pH 7.4
(Rockland Inc, Gilbertsville PA) with 0.1% Tween-20 and 5%
BSA (Sigma, St. Louis, MO). Serum samples were diluted
four-fold in Tris-buffered saline with Tween-20 (TBS-t). The
EpoxyES coated-slides were placed in the ProPlate™ system
and washed twice with TBS-t and blocked for 30 min at room
temperature with 0.5% dry milk, 0.5% BSA (Sigma) in TBS-t
on a rotating platform. The block was removed and the
standards and diluted serum samples were placed on the
antibody microarray (100 mL per well) in duplicate. The
arrays were covered and placed on a rotating platform at 47C
overnight. Arrays were washed at least three times with TBS-
t and detection antibodies diluted in block were incubated for
2 h on a rotating platform at room temperature. Arrays were
washed as above and detection antibody was hybridized with
Alexa Fluor 647-strepavidin (Molecular Probes) diluted
1:2500 in block and incubated at room temperature on a
rotating platform in the dark. Arrays were washed as above,
removed from the ProPlate™ system, dipped in TBS, dipped
in double distilled H2O and dried using compressed air.
Slides were stored in the dark at room temperature until they
could be scanned.
2.4 Antibody microarray scanning, quantification and
analysis
Slides were scanned on an Axon 4000B using GenePix 6.0
(Axon Instruments/Molecular Devices, Sunnyvale, CA). Sin-
gle laser was used and laser intensity was adjusted so the
highest standards were not saturated and the same intensity
was used for all slides processed during the same experiment.
GenePix 6.0 (Axon Instrument/Molecular Devices) and the
antibody array gal file were used to quantify the antibody
arrays. MFI data minus the background was imported into
PrismGraph 4.0 (GraphPad Software, Inc. San Diego, CA).
Standard curve and unknowns were calculated using the
curve fitting function and quantifiable analytes were plotted
based on concentration. Samples that were not within the
standard linear range or had a high non-specific background
in the isotype antibody controls were excluded from analysis.
Normal and vasculitis patient serum were compared using a
two-tailed t-test and considered significant if p,0.05.
3 Results
3.1 Antibody microarray development
An overall view of a scanned ProPlate antibody microarray
used for titration with standard dilution series is shown in
Fig. 1A. Initial titration of the amount of antibody spotted
showed that the concentration of the capture antibody can
affect the standard curve as illustrated with the TNF-a anti-
body (Fig. 1B). The optimal amount of capture antibody
spotted was independent of the host animal (not shown).
Antibody pair performance was relative to the capture and
detection antibodies. Antibody (capture or detection) con-
centrations that were too high saturated the curve early and
usually had a high background, whereas concentrations too
low negatively impacted the limit of detection.
Titration of the detection antibodies as illustrated with the
IL-5 antibody (Fig. 1C) illustrates that both the capture and
secondary antibody concentrations could be determined con-
currently. This allows for the optimization of both capture and
detection and to quickly determine if there are quantifiable dif-
ferences. No significant changes were made when the capture
and detection antibodies were titrated individually. An opti-
mized antibody pair had: (i) large linear range of detection, (ii)
low limit of detection (i.e. ,50 pg/mL), (iii) no cross-reactivity,
(iv) percent recovery between 85–115 % and (v) a low back-
ground (usually ,1000 MFI). No cross reactivity was seen
using 1000 pg/mL of standard proteins individually spiked
into TBS-t with 5% BSA. The list of 24 proteins for which opti-
mized antibody pairs could be identified is shown in Table 1.
Table 1 also lists the detection range, percent recovery, and
curve fit (r2) for each of the optimized antibody pairs.
A log transformation of the protein concentration and
curve fitting of the standards showed that the representative
set of the standards had an r2.0.95 (Fig. 2). This shows the
log of the concentration (x-axis) with the MFI minus back-
ground. Proteins with an r2,0.95 were used to determine
relative (non-quantitative) expression based on the MFI.
Four proteins that did not perform according to our a priori
determined quantitative standards, which were C5a, CD62E,
CD62I and CD62P (Table 1).
3.2 Analysis of patient samples
Vasculitis patient and normal serum samples were analyzed
alongside standard protein dilution series to allow for quan-
tification of the samples. Each patient sample was replicated
three times per plate and repeated an additional 3–4 times
with different plates. Analysis of the standard curves showed
that the majority of standards performed as expected from
the initial experiments described above. The standards
showed no statistical difference between the titration experi-
ments and the experimental ones. Analysis of patient sam-
ples was completed by back-calculating the concentration
base on the standard curve and multiplying by the dilution
factor (four-fold). If a sample reacted with the non-specific
IgG control antibodies, the sample was excluded. This
accounted for 10% of the normal and 11% of the WG sam-
ples. Non-specific reactivity showed no connection between
well location or print lot number and therefore was probably
due to the samples. Individual protein levels that were out-
side the standard curve were excluded, however in our hands
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Figure 1. Optimization of cap-
ture and detection antibody
concentrations. A representa-
tive standard curve antibody
array slide is shown in (A). A
representative effect of capture
antibody concentration on MFI
is shown using TNF-a and con-
centration effects was on MFI
determined for all capture anti-
bodies (B). The effect of the sec-
ondary (detection) antibody
dilution on MFI is shown in (C)
with IL-5 being the representa-
tive protein analyte.
with the four-fold dilution this rarely occurred. Expression
levels of the specific proteins in most cases followed
expected expression patterns compared to what has been
previously reported in the literature and the majority of the
normal samples fell within expected expression levels
(Fig. 3). The array showed a high degree of reproducibility
with ,5% coefficient of variation per plate and ,10% be-
tween ProPlate runs. Figure 3 shows the quantifiable
serum proteins as a whisker plot to show the total varia-
tion, 25th, 50th, and 75th percentiles. The graphs are sepa-
rated into three parts to aid in readability. The patient
population with vasculitis showed a significantly (p,0.05)
increased amount of: angiotensin I converting enzyme
(ACE), IFN-g, IL-8, s-ICAM and s-VCAM in the serum as
compared to the controls. The quantified values for these
five proteins are shown in Table 2 along with the standard
error of the mean and fold difference. The fold differences
between the normal and the WG patients ranged between
1.8-fold for the ACE expression to 12.1-fold for IL-8. Addi-
tionally, there were non-significant increases seen in the
expression of: IL-1b, IL-2, IL-10, IL-6 MIP-1b, TGF-b, TNF-
a, VEGF and E-selectin in the vasculitis patients as com-
pared to controls (Fig. 3). Not all proteins were up regu-
lated and IL-4 and IL-5 showed non-significant decreases
in the WG patient group as compared to the healthy con-
trols. Figure 4 shows a whisker plot of the non-quantifiable
serum proteins evaluated with MFI plotted instead of con-
centration in pg/mL. No significant differences were seen
in the non-quantitative group. However, a possible trend of
increased C5a was seen in WG but was not statistically
significant.
4 Discussion
This study is the first to utilize antibody microarrays to
screen serum samples from patients with WG which
allows for the rapid analysis of multiple proteins in the
serum in a high-throughput manner without making any a
priori assumptions about which proteins to assess. Using
this technology we have found that the levels of several
proteins in the serum are significantly increased in
patients with WG as compared to controls including: ACE,
IFN-g, IL-8, s-ICAM and s-VCAM. Thus, it appears as if
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Table 1. Summary of the antibody pair performance.
Proteins Catalog number Range (pg/mL) Percent recovery Curve fit r2
ACE DY 929 ,2.4–10000 93.1 0.979
C5a AF/BAF 2037 .1667 ND ,0.95
E-Selectin/CD62E DY 724 .1667 ND ,0.95
IFN-g DY 285 6.86–5000 89.4 0.981
IL-1a DY 200 2.4–10000 107.9 0.974
IL-1b DY 201 ,1.2–5000 95.2 0.971
IL-2 DY 202 ,1.2–5000 86.8 0.961
IL-4 DY 204 6.86–5000 87.7 0.959
IL-5 DY 205 1.2–5000 102.4 0.953
IL-6 DY 206 ,1.2–5000 95.1 0.951
CXCL8/IL-8 DY 208 2.4–5000 96.1 0.961
IL-10 DY 217B 6.86–5000 87.3 0.973
IL-13 DY 213 1.2–5000 86.4 0.964
Leptin DY 398 61.7–10000 90.9 0.953
L-Selectin/CD62L DY 728 .555 86.2 0.933
CCL3/MIP-1a DY 270 1.2–5000 89.5 0.978
CCL4/MIP-1b DY 271 1.2–5000 93.6 0.99
P-Selectin/CD62P DY 137 .1667 ND ,0.95
s-ICAM DY 720 61.7–5000 91.9 0.965
TGF-b DY 239 1.2–5000 101.7 0.99
TNF-a DY 210 6.86–5000 95.2 0.99
s-VCAM DY 809 6.86–5000 89.4 0.976
VEGF DY 293B 6.86–5000 96.6 0.989
XIAP DY 822 6.86–5000 85.7 0.975
Antibody pairs were tested in either phosphate buffered saline, TBS-t with 5% BSA or spiked into normal human
serum. Range was determined as the lowest level of detection that was greater than two-SDs from the 0 standard
and highest limit of detection was determined as the last standard that was not saturated and with a MFI greater
than the previous standard. Percent recovery was determined by spiking the standard proteins into both TBS-t
with 5% BSA and normal human serum at 1000 pg/mL normal human serum percent recovery is shown. Antibody
pairs with limit of detection .1000 pg/mL did not have the percent recovery determined (ND). Curve fit was
determined on analytes using a log transform of the standard dilution in TBS-t with 5% BSA. ND = not determined.
All data is the mean of at least four independent experiments.
the use of the antibody array technology provides an ideal
platform for which to assess protein levels in biofluids in
these patients and may differentiate this complex disease
process.
Antibody microarrays are a customizable high-through-
put screening technology that can be applied to a range of
samples. This technology can be easily applied to existing
matched antibody pairs and with minimal difficulty applied
to pairs of unmatched pairs antibodies. The majority of the
matched antibody sets performed quantitatively and had a
low background, had low limits of detection, and performed
similarly to classical single ELISA’s with no significant dif-
ferences in range of detections. One exception was s-VCAM
that had a background 50 to 100-fold greater than the oth-
ers, however this antibody still performed well in all other
tests and was considered quantitative. Other antibodies
such as: C5a, CD62E. CD62L and CD62P did not perform
up to our acceptance criteria. This was expected from the
C5a antibody pair since the capture and detection antibodies
were the same but the detection antibody was biotinylated.
The C5a antibodies used in the antibody microarray per-
formed similar to classical ELISA in range of detection. The
CD62 family performed better at the higher concentrations
but lacked the lower limit of detection seen with the other
analytes and did not meet our lower limit of detection
acceptance criteria.
The application of the custom antibody microarray was
straightforward once the optimal antibody concentration for
the array was developed. A mixture of standard proteins were
diluted to generate an eight-point standard curve and hybri-
dized in duplicate along side the serum samples similar to
classical ELISA protocols. The MFI was determined and
samples non-specifically cross-reacting with the background
controls were excluded. While uncommon, in 10 to 11% of
the samples from both groups had a high non-specific back-
ground and cross-reactivity with the isotype control anti-
bodies was seen in both groups. The non-specific back-
ground may be decreased by using additional blocking,
increasing the dilution, or may be indicative of antibodies
against animal immunoglobulin. As expected, some of the
serum proteins were outside the limit of detection on the
antibody pairs in a selected sample but this did not affect the
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Figure 2. Calculation of stand-
ard curves. Representative
standard curves shown are
using protein standard curve
(including 0) diluted in TBS-t
with 5% BSA. Mean MFI was log
transformed and 4-parameter
logistic calculation was used to
curve fit (lines). Curve fit data
was generated from representa-
tive standard proteins is shown
curve fit analysis with a linear y
and logarithmic x-axis. Curve fit
data was generated for all pro-
tein analytes. Shown is the
mean of four independent
experiments with error bars
indicating 6 SEM.
majority of samples or proteins. Knowing the expected con-
centration range and designing the antibody microarray
antibody pairs is one aspect that should be accounted for in
the initial design. The antibody microarray performed well
when used for patient samples and was quantifiable for most
(21 out of 24) of proteins tested.
The proteins ACE, IFN-g, IL-8, s-ICAM and s-VCAM
show statistical differences between the normal and WG
patients (p,0.05). In fact these proteins are markedly
increased in the serum of WG patients as compared to con-
trols with fold change increases ranging from 1.8–12.1. These
fold increases have also been found to be significant in other
studies measuring serum protein cytokine levels in other dis-
eases [43]. Several other inflammatory related proteins are
also increased in the patients with WG but they did not
achieve statistical significance. This indicates the need for a
serial, controlled prospective study using antibody micro-
arrays with vasculitic patients. Interestingly, increased ACE
expression was not observed in patients with positive pANCA
titers that had diseases such as systemic lupus erythematosus
(SLE) or inflammatory bowel disease while the WG may have
been in possible remission due to treatment [21].
Most studies to date have utilized isolated peripheral
blood mononuclear cells in WG patients to assess their pro-
duction of Th1 and Th2 cytokines. These studies have found
evidence of a primarily Th1 systemic response in these
patients with primarily CD41 T cells producing IFN-g, IL-12
and TNF-a. [9, 25]. In terms of assessing cytokine levels in
plasma or serum from WG patients using ELISA based sys-
tems there are a limited number of preliminary studies that
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Figure 3. Analysis of quantita-
tive analytes. Normal human
serum and WG (vasculitis)
serum was analyzed on the anti-
body microarray. Concentration
was calculated based on MFI
and curve fit equation generated
by the protein standards. The
mean of duplicate wells with
three replicate spots per well
was plotted on a whisker plot
showing the total variability,
25th, 50th and 75th percentiles
with concentration (y-axis) plot-
ted in a log scale to allow for
plotting of a range of different
analytes due to difference in
concentration. Statistical differ-
ences were determined using a
two-tailed t-test and considered
significant if p,0.05 (*). Proteins
analyzed were broken into three
different graphs (A, B, and C).
Table 2. Quantified values of statistically different analytes





ACE-I 3290.1(6 214.3) 5927.1(6 283.0) 11.8
IFN-g 23.4 (6 3.4) 151.4 (6 19.5) 16.5
IL-8 107.3 (6 9.0) 1294.0 (6 55.3) 112.1
s-ICAM 6195.2 (6 533.7) 12679.4 (6 870.7) 12
s-VCAM 120.7 (6 26.5) 674.3 (6 28.8) 15.6
Five proteins in serum were found to have statistically different
expression based on a two-tailed t-test (p,0.05). The quantified
values along with standard error of the mean (in parentheses) are
shown and allow for comparison of normal and WG serum sam-
ples. The fold change shows the difference between the normal
and affected patients analyte expression with positive (1) indi-
cating an increase in WG patients serum.
assessed a relatively small number of cytokines from a small
cohort of WG patients. Two studies showed elevations in IL-
6, IL-8 and IL-10 and TNF-a proteins [44, 45]. In another
study where only three patients were assessed increased cir-
culating levels of IFN-a and IL-2 could be detected whereas
IFN-g and TNF-a levels were not elevated [37]. In terms of
measuring soluble adhesion molecules only one study to
date has looked at this and found that WG patients had ele-
vations in s-ICAM but not s-VCAM [28]. Thus the studies to
date have been largely preliminary with different results for
some of the same proteins.
Figure 4. Analysis of the non-quantitative analytes. Three ana-
lytes were not quantitative due to poor performance on the
standard curve analysis. MFI was used to determine if there are
differences in expression. The mean of duplicate wells with three
replicate spots per well was plotted on a whisker plot showing
the total variability, 25th, 50th and 75th percentiles. Statistical
analysis showed no significant differences between the normal
and the WG (vasculitis) patient serum.
The increased expression of ACE in the WG samples or
other types of vasculitis has not been reported to date and is
potentially of great interest since ACE is expressed in high
levels by endothelial cells. ACE inhibitors have been impli-
cated in vasculitic lesions and one case report showed a link
between ACE and granulomatosis disease of unknown etiol-
ogy [46–48]. Increased expression of ACE expression in the
WG patients is a more than likely a reaction to the disease
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state and not gene polymorphisms [49]. A possible reason for
increased ACE levels could be steroidal anti-inflammatory
treatment but this is unlikely since prednisolone has been
shown to decrease ACE in asthmatic patients [50]. Addition-
ally, the angiotensin system has been implicated in endothe-
lial cell damage, vascular inflammation and may be involved
in end organ damage [51]. The exact role of ACE in the
development of vasculitis remains to be determined.
The expression of TGF-b1 has been shown to be elevated
in systemic vasculitis including WG [34]. The antibody
microarray detected similar amounts of TGF-b as was report-
ed, but in our study there were no statistical differences be-
tween the normal and the WG samples. Possible explana-
tions include variability in the normal and vasculitis samples
and the fact that the antibody array measures total TGF-b
instead of active. Additionally, the expression of several other
cytokines implicated in vasculitis such as IL-1b, IL-2, IL-10,
IL-6 MIP-1b, TGF-b, TNF-a, VEGF and e-Selectin showed no
differences between controls and vasculitis patients. Inter-
estingly, the normal population showed a wide range of
expression in a few proteins probably due to undisclosed
sub-clinical illness or reflects the variability of expression.
However, the mean expression of the proteins in the normal
human serum group was within the expected normal range.
The expression of several cytokines have been implicated in
vasculitis and remain to be investigated with a prospective
serial study using high-throughput proteomic technology
[50–54].
In summary, screening of WG patient sera with an opti-
mized antibody array revealed significant upregulation of
ACE, IFN-y, IL-8, s-ICAM and s-VCAM as compared to a
control population. The increased expression on many of
these proteins such as ACE and s-VCAM in these patients
has not been previously described and suggests that these
proteins may be possible selective markers of vascular injury.
The development, implementation and screening of patient
samples using antibody microarrays is a straightforward
process and further studies will use this technology to deter-
mine if other types of vasculitis also have similar patterns of
protein expression and whether this pattern of protein
expression is specific for WG.
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